NR1H4 and metabolic dysfunction-associated steatotic liver disease: Recent studies highlight the critical role of FXR agonists in treating a variety of liver-related conditions, including primary sclerosing cholangitis, primary biliary cirrhosis, cholestatic liver disorders, and nonalcoholic fatty liver disease, and preventing gallstone formation.